Concepedia

Double‐blind, placebo‐controlled, dose‐ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber

Wally Meyer, Annemie Narkus, A. Salapatek, D. Häfner

Allergy · 2013 · 70 citations · 23 references

DOI

Abstract

Considering efficacy, immunological response, and tolerability, a maintenance dose of 80 μg of rBet v 1-FV appears to be the ideal dose for allergen immunotherapy in birch pollen allergic patients.

References

23

Standards for practical allergen‐specific immunotherapy

Emilio Álvarez-Cuesta, Jean Bousquet, Giorgio Walter Canonica et al. · Allergy · 2006 · 401 citations

, , +4

Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I

Philippe‐Jean Bousquet, S Chinn, C. Janson et al. · Allergy · 2007 · 392 citations

GA<sup>2</sup>LEN skin test study I: GA²LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe

L. M. Heinzerling, G. J. Burbach, Günter Edenharter et al. · Allergy · 2009 · 371 citations

Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis

Gabrielle Pauli, Tina H. Larsen, S. Rak et al. · Journal of Allergy and Clinical Immunology · 2008 · 310 citations

, , +5

IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of <i>Betula verrucosa</i>*

Erika Jensen‐Jarolim, Helmut Rumpold, Anne Endler et al. · Allergy · 1989 · 217 citations

, , +18